Cadila gets USFDA nod for Esomeprazole Magnesium capsule
Zydus Cadila informed the bourses that it has received final approval from the USFDA to market Esomeprazole Magnesium Delayed-Release Capsule, 25 mg and 40 mg. The said tablet is used to treat certain stomach and esophagus problems like acid reflux, ulcers.
The group has 266 approvals and has so far filed over 350 ANDAs since the commencement of the filing process.
Cadila's FY18 revenue mix comprised US Formulations (50 per cent), India Formulations (29 per cent), EMB Formulations (6 per cent), Animal Health (4 per cent), Wellness (4 per cent), API (3 per cent), Alliances (2 per cent) and Europe Formulations (2 per cent).
During the recently concluded quarter Q3FY19, the company has witnessed 10 per cent yoy increase in its revenue. However, the bottomline has declined by 6 per cent on yoy basis. The company is going to announce March 2019 results on May 29, 2019.
On Thursday, the stock of Cadila Healthcare opened at Rs. 252 per share and made an intraday low of Rs. 251.05 on the BSE. At 12:27 hours, the stock was trading at Rs. 251.40, up marginally on the BSE. The company had hit its 52-week high of Rs. 432.40 on September 10, 2018 and its 52-week low of Rs. 241.55 on May 16, 2019 on the BSE.